Truist analyst Richard Newitter downgraded Inspire Medical (INSP) to Hold from Buy with a $96 price target
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical drops as CMS correction triggers Oppenheimer downgrade
- Evercore ISI says Inspire Medical guide should be intact despite CMS correction
- Inspire Medical downgraded at Oppenheimer after CMS issues correction
- Inspire Medical downgraded to Perform from Outperform at Oppenheimer
- Inspire Medical price target lowered to $145 from $160 at Wells Fargo